Publications by authors named "Hitoshi Sase"

Claim this Profile
S
Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA display.
Mirai Kage, Ryuji Hayashi, Atsushi Matsuo, Minoru Tamiya, Shino Kuramoto, Hitoshi Sase

Bioorg Med Chem· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a New Methodology to Create Oral Drugs beyond the Rule of 5 for Intracellular Tough Targets.
Atsushi Ohta, Mikimasa Tanada, Shojiro Shinohara, Yuya Morita, Kazuhiko Nakano, Hitoshi Sase

J Am Chem Soc· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor.
Mikimasa Tanada, Minoru Tamiya, Atsushi Matsuo, Aya Chiyoda, Koji Takano, Hitoshi Sase

J Am Chem Soc· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.
Hiroshi Tanaka, Hitoshi Sase, Toshiyuki Tsukaguchi, Masami Hasegawa, Hiromi Tanimura

Mol Cancer Ther· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in -Amplified Gastric Cancer.
Hitoshi Sase, Yoshito Nakanishi, Satoshi Aida, Kana Horiguchi-Takei, Nukinori Akiyama

Mol Cancer Ther· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.
Yoshito Nakanishi, Hideaki Mizuno, Hitoshi Sase, Toshihiko Fujii, Kiyoaki Sakata

Mol Cancer Ther· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi, Toshihiko Fujii, Kiyoaki Sakata, Hitoshi Sase

Mol Cancer Ther· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of targets of Prox1 during in vitro vascular differentiation from embryonic stem cells: functional roles of HoxD8 in lymphangiogenesis.
Kaori Harada, Tomoko Yamazaki, Caname Iwata, Yasuhiro Yoshimatsu, Hitoshi Sase

J Cell Sci· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VEGFR2-PLCgamma1 axis is essential for endothelial specification of VEGFR2+ vascular progenitor cells.
Hitoshi Sase, Tetsuro Watabe, Kyoko Kawasaki, Kohei Miyazono, Keiji Miyazawa

J Cell Sci· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ras signaling directs endothelial specification of VEGFR2+ vascular progenitor cells.
Kyoko Kawasaki, Tetsuro Watabe, Hitoshi Sase, Masanori Hirashima, Hiroshi Koide

J Cell Biol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arkadia induces degradation of SnoN and c-Ski to enhance transforming growth factor-beta signaling.
Yoshiko Nagano, Konstantinos J Mavrakis, Kian Leong Lee, Tomoko Fujii, Daizo Koinuma, Hitoshi Sase

J Biol Chem· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis